$3.10 Billion
Global brain tumor therapeutics market size.
0
Approved treatments considered curative.
6.90%
Current 5-year survival rate for Glioblastoma.
Brain cancer affects over 300,000 people per year and is the most expensive cancer to treat, yet remains critically underfunded and resistant to current therapies.
Brain cancer, particularly malignant gliomas like glioblastoma, remains one of the most complex and underfunded areas in oncology. Despite devastating survival rates, only 6.9% of GBM patients live past five years, and brain cancer being the most exp...
LDL Receptor Appearance as a Diagnostic Early Detector
High-grade gliomas overexpress LDL receptors to fuel tumor growth, especially near blood vessels. LDLR-targeted PET/SPECT imaging agents for early, non-invasive detection could enable faster diagnosis and improved outcomes for glioma and metastatic brain tumor patients.
Machine Learning-Assisted Early Detection
AI texture analysis has shown promise in improving GBM diagnosis, but broader validation is needed. This study evaluates performance across diverse datasets and staining methods, integrating explainable AI to boost interpretability and enable reliable, scalable clinical adoption.
Assessing GBM Isolation Through Digital Phenotyping
By analyzing passive mobile data on patient mobility and sociability, this research aims to link digital phenotypes with glioblastoma progression, recurrence, and QoL. Success could lead to IP for hospital- and pharma-grade tools that outperform traditional monitoring methods.
GlioDAO captures value by funding early-stage, translational brain cancer research and securing rights to the resulting intellectual property through IP-NFTs. As these assets mature, GlioDAO can negotiate out-licensing agreements with biotech or phar...
Nature Reviews Clinical Oncology
Challenges to curing primary brain tumours
Cellular & Molecular Immunology
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Neuro-Oncology Advances
